Use fundamental data analysis to confirm all available indicators of Virtus LifeSci Biotech to find out if markets are presently mispricing the entity. We found ten available drivers for Virtus LifeSci Biotech Clinical Trls ETF which can be compared to its competition. Please use Virtus LifeSci Total Asset, and the relationship between Price to Sales and Three Year Return to make a decision on weather Virtus LifeSci Biotech is priced fairly. Use Virtus LifeSci to enhance returns of your portfolios. The etf experiences normal upward fluctuation. Check odds of Virtus LifeSci to be traded at $27.74 in 30 days
Virtus LifeSci Biotech Clinical Trls ETF is fourth largest ETF in price to earning as compared to similar ETFs. It is rated below average in price to sales as compared to similar ETFs fabricating about 0.05 of Price to Sales per Price to Earning. The ratio of Price to Earning to Price to Sales for Virtus LifeSci Biotech Clinical Trls ETF is roughly 20.04
Virtus LifeSci Biotech Systematic Risk
The output start index for this execution was twelve with a total number of output elements of twenty-seven. The Beta measures systematic risk based on how returns on Virtus LifeSci Biotech correlated with the market. If Beta is less than 0 Virtus LifeSci generally moves in the opposite direction as compared to the market. If Virtus LifeSci Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Virtus LifeSci Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Virtus LifeSci is generally in the same direction as the market. If Beta > 1 Virtus LifeSci moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
Virtus LifeSci Financial Distress Probability
Chance of Financial Distress
Virtus LifeSci Biotech Clinical Trls ETF has less than 42 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info